Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system.

Jolanta Powierska-Czarny; Danuta Miścicka-Sliwka; Jakub Czarny; Tomasz Grzybowski; Marcin Wozniak; Gerard Drewa; Włodzimierz Czechowicz; Jan Sir

doi:10.18388/abp.2003_3643

Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system.

Jolanta Powierska-Czarny Department of Human Biology, The Ludwik Rydygier Medical University of Bydgoszcz, Bydgoszcz, Poland. jolanta_powierska@o2.pl;
Danuta Miścicka-Sliwka
Jakub Czarny
Tomasz Grzybowski
Marcin Wozniak
Gerard Drewa
Włodzimierz Czechowicz
Jan Sir

DOI: https://doi.org/10.18388/abp.2003_3643

Abstract

Analysis of microsatellite instability (MI) and loss of heterozygosity (LOH) is recommended for screening patients with sporadic and hereditary malignancies. This study shows an application of a fluorescent hexaplex PCR system for microsatellite typing on A.L.F. DNA Sequencer (Pharmacia Biotech). This technique detects changes in microsatellites providing a time-efficient, reliable and accurate method for MI and LOH analyses. The Fragment Manager software was used for automated size calculation and quantitation of DNA fragments, enabling rapid and precise measurement of allelic ratios. We examined 70 breast cancer and 70 control DNA specimens, classified all the patterns of microsatellite alterations, and set up MI and LOH assessment criteria for the automated multiplex fluorescent method.

Published

2003-12-31

Issue

Vol. 50 No. 4 (2003)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.